Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients

BACKGROUND: Acute graft-versus-host disease (aGVHD), a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT), often occurs within 100 days of HSCT. While steroids are typically used as first-line treatment, there is no consensus on second-line steroid-refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Grabner, Michael, Strati, Eric, Sandman, Karen, Forsythe, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390991/
https://www.ncbi.nlm.nih.gov/pubmed/33908282
http://dx.doi.org/10.18553/jmcp.2021.27.5.607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390991/
https://www.ncbi.nlm.nih.gov/pubmed/33908282
http://dx.doi.org/10.18553/jmcp.2021.27.5.607

Ejemplares similares